Syntax Research, Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Syntax Research, Inc.
- $148 Billion
- Q3 2024
A detailed history of Syntax Research, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 245 shares of REGN stock, worth $175,586. This represents 0.17% of its overall portfolio holdings.
Number of Shares
245
Previous 345
28.99%
Holding current value
$175,586
Previous $363 Million
28.97%
% of portfolio
0.17%
Previous 0.29%
Shares
2 transactions
Others Institutions Holding REGN
# of Institutions
1,534Shares Held
83.6MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.68 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.05 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.37 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.51 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.08 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $76.8B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...